EXINI Diagnostics

We empower patients for better healthcare with Artificial Intelligence

25 years of experience in developing certified medical device software

EXINI Diagnostics AB was established in 1999 to develop and market AI methods for automated analysis of diagnostic images developed by a research group at Lund University. We have developed automated analysis platforms for PSMA, cardiac, brain and bone scans. Now, the company has more than 800 sites worldwide,
Visit our product pages to find out more about our software.

EXINI is a wholly owned subsidiary of Lantheus Holdings, Inc.

Lantheus logo





Pylarify AI®

Areas of Expertise



Pharma service

Interested in partnering with EXINI?

What do the experts say about the future of AI in medical imaging?

Providing a quantifiable and reproducible assessment of PSMA uptake and distribution in the body is critical here to enable precision oncology in prostate cancer.

Andrew J. Armstrong, MD.

Divisions of Medical Urology and Oncology, Duke University, NC, USA

The quantification and standardization of PSMA scan reports is a major step forward to enhance the reproducibility and timeliness of scan interpretations.

Matthew B. Rettig, MD.

Professor of medicine and urology, David Geffen School of Medicine at UCLA, CA, USA

Modern chess AI running on even modest hardware can easily defeat the greatest human grand masters. There’s no reason to think the eventual outcome will be any different with diagnostic imaging. PSMA-AI is a step towards that goal.

Stephan Probst

Chief of Nuclear Medicine, Jewish General Hospital, Montréal, Canada.

Artificial intelligence is essential to advance molecular imaging in cancer, to capture the power of MI for detection and quantitating molecular expression of individual tumor lesions within the prostate cancer patient.

Steven M. Larson, MD.

Department of Radiology, Memorial Sloan Kettering Cancer Center, NY, USA


New version released of PYLARIFY AI® (aPROMISE)

New version released of PYLARIFY AI® (aPROMISE)

We have now released a new version of PYLARIFY AI® for prostate cancer analysis. The new version include features such as: Parallel Study Review Select all suggested hotspots CT Measurement Tool...